Heterozygous family hypercholesterolaemia: Study of use of statins under clinical practice conditions;Hipercolesterolemia familiar heterocigota: Estudio de utilización de estatinas en condiciones de práctica clínica

Atencion Primaria

Volumn 38, Issue 6, 2006, Pages 333-338

  Portela Romero, Manuel ^a,c   Pombo Romero, Julio ^a   Bugarín González, Rosendo ^b   Tasende Souto, Margarita ^a  

^a Dirección General de Farmacia y Productos Sanitarios   (Spain)

^b Servicio Galego de Saúde   (Spain)

^c NONE   (Spain)

Author keywords

Defined daily dose; Heterozygous family hypercholesterolaemia; Statins

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; HETEROZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; RETROSPECTIVE STUDY;

EID: 33751010786     PISSN: 02126567     EISSN: None     Source Type: Journal    
DOI: 10.1157/13093370     Document Type: Article

References (18)

1. Instituto Nacional de Estadística Defunciones según la Causa de Muerte, 1992. Tomo I. Resultados Básicos. Madrid: Instituto Nacional de Estadística; 1995.
2. Dodu SRA. Emergence of cardiovascular disease developing countries. Cardiology. 1988;75:56-64.
3. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J. 1998;94:1434-503.
4. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. En: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease. New York: Mc-Graw-Hill; 1995. p. 1981-2030.
5. Hobs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat. 1992;1:445-6.
6. Südhof TC, Goldstein JL, Brown MS, Russell DW. The LDL receptor gene: a mosaic of exons shared with different proteins. Science. 1983;228:815-22.
7. Goldstein JL, Brown MS. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci USA. 1973;70: 2804-8.
8. Fundación Hipercolesterolemia Familiar. Genética de la hipercolesterolemia familiar [en línea]. 2005 [accedido Mar 2005] Disponible en :http://www.colesterolfamiliar.com/n/cgi-bin/ver.asp?opcion= 0202〉.
9. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. En: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. New York: Mc-Graw-Hill; 2001. p. 2863-913.
10. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolemia: implications for clinical management. Atherosclerosis. 1999;142:105-15.
11. Fundación Hipercolesterolemia Familiar. Entermedad coronaria [en línea] [accedido Abr 2005]. Disponible en: http://www.colesterolfamiliar. com/n/cgi-bin/ver.asp?opcion=010301
12. Instituto Nacional de Estadistica [en línea] 2001 [accedido Mar 2005]. Disponible en: http://www.ine.es/
13. WHO. Human Genetics Program. Familial hypercholesterolaemia, a global perspectiva. Geneve: WHO; 1999.
14. Gómez Gerique JA, Gutiérrez-Fuentes JA, Montoya T, Porres A, Rueda A, Avellaneda A, et al. Perfil lipidico de la población española: estudio DRECE (Dieta y Riesgo de Enfermedad Cardiovascular en España). Med Clin (Barc). 1999;113:730-5.
15. Real Decreto 1348/2003, de 31 de octubre, por el que se adapta la clasificación anatómica de medicamentos al sistema de clasificación ATC. Boletin Oficial del Estado, número 264, de 4 de Noviembre de 2003.
16. Who Collaborating Centre for drug statistics methodology [en línea] 2005. [accedido 23 Mar 2005]. Disponible en: http://www.whocc.no/ atcddd/
17. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-39.
18. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al, Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35.